Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123053 · ClinicalTrials.gov registry record · Phase 2
Firdapse for Post-BOTOX Vocal Weakness
A Phase 2 study of Vocal Weakness(Post-BOTOX Injection), sponsored by Augusta University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05123053 is a Phase 2 study of Vocal Weakness(Post-BOTOX Injection) that has completed, run by Augusta University. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05123053, a Phase 2 study of Vocal Weakness(Post-BOTOX Injection), has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Botox injections into the thyroarytenoid muscle are a predictable and effective treatment for SD, but typically result in transient symptoms of voice weakness and breathiness during the first 2-3 weeks after injection. Investigators hypothesize that voice weakness and breathiness after Botox treatment can be alleviated using amifampridine.
Conditions Studied
Interventions
- DRUG Amifampridine
Study Locations (1)
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05123053
The ClinicalTrials.gov registry entry for NCT05123053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vocal Weakness(Post-BOTOX Injection) appearing as the primary indexed condition, and to 1 intervention - of which Amifampridine is the first listed.
NCT05123053 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05123053 about?
NCT05123053 is a clinical study titled "Firdapse for Post-BOTOX Vocal Weakness". Botox injections into the thyroarytenoid muscle are a predictable and effective treatment for SD, but typically result in transient symptoms of voice weakness and breathiness during the first 2-3 weeks after injection. Investigators hypothesize that voice weakness and breathiness after Botox treatme...
What is the current status of trial NCT05123053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-10-28. Estimated completion is 2025-09-23.
What conditions does trial NCT05123053 study?
This clinical trial studies the following conditions: Vocal Weakness(Post-BOTOX Injection).
What interventions are being tested in trial NCT05123053?
The interventions under investigation include: Amifampridine (DRUG).
Who is sponsoring clinical trial NCT05123053?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05123053 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.